The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats.

Steven T Pittenger, Lindsey C Zeplin, Linda P Dwoskin, Rick A Bevins
Author Information
  1. Steven T Pittenger: Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA.
  2. Lindsey C Zeplin: Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA.
  3. Linda P Dwoskin: College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY, 40536-0596, USA.
  4. Rick A Bevins: Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA. rbevins1@unl.edu.

Abstract

RATIONALE: Pharmacotherapies are often utilized to aid in smoking cessation, and switching medication when treating nicotine dependence has become more commonplace. Although common, little is known about the impact of the initial therapy on the effects of the subsequent therapy.
OBJECTIVES: To begin to fill this gap in our understanding, this project determined how switching compounds that share stimulus elements with nicotine during extinction altered extinction responding and generalization of this extinction back to nicotine.
METHODS: Rats were trained in a discriminated goal-tracking task where nicotine administration was followed by intermittent sucrose access; sucrose was withheld following saline administration. In experiment 1, nornicotine supplanted nicotine in extinction sessions 1-3 and then a switch to varenicline on extinction sessions 4-6 was examined. In experiment 2, the reverse was investigated; varenicline to start extinction and then a switch to nornicotine. Generalization of extinction back to the nicotine stimulus was then assessed by generating a cumulative dose-effect curve.
RESULTS: Generalization of extinction back to the training nicotine stimulus was greater if nornicotine had been received at any point in extinction compared to only receiving varenicline. Whereas, extinction with varenicline alone showed more generalization to lower doses of nicotine.
CONCLUSIONS: A switch in cessation pharmacotherapy during extinction did not impede or enhance generalization back to the nicotine-training stimulus. The nornicotine stimulus appears to share more stimulus overlap with the 0.4 mg/kg nicotine stimulus and varenicline may share more overlap with lower nicotine doses.

Keywords

References

  1. Behav Pharmacol. 2007 Dec;18(8):707-16 [PMID: 17989508]
  2. J Neurochem. 2007 Apr;101(1):160-7 [PMID: 17241116]
  3. Neuropharmacology. 2007 Mar;52(3):985-94 [PMID: 17157884]
  4. Behav Pharmacol. 1996 Mar;7(2):144-154 [PMID: 11224406]
  5. Nicotine Tob Res. 2013 Jun;15(6):1146-50 [PMID: 23128516]
  6. Pharmacol Biochem Behav. 2015 Mar;130:84-9 [PMID: 25616031]
  7. J Psychopharmacol. 2010 Jun;24(6):817-28 [PMID: 19304864]
  8. Psychopharmacologia. 1974;40(2):109-20 [PMID: 4449931]
  9. Psychopharmacology (Berl). 1984;84(3):413-9 [PMID: 6440189]
  10. Arch Gen Psychiatry. 2009 Nov;66(11):1253-62 [PMID: 19884613]
  11. Psychopharmacology (Berl). 2004 Feb;172(1):108-17 [PMID: 14530902]
  12. J Med Chem. 2005 May 19;48(10):3474-7 [PMID: 15887955]
  13. Drug Metab Dispos. 1999 Dec;27(12):1448-55 [PMID: 10570026]
  14. JAMA. 2014 Jan 8;311(2):155-63 [PMID: 24399554]
  15. Behav Pharmacol. 2006 Mar;17(2):161-72 [PMID: 16495724]
  16. JAMA. 2014 Jul;312(2):155-61 [PMID: 25005652]
  17. JAMA. 2012 Oct 17;308(15):1573-80 [PMID: 23073954]
  18. J Neurochem. 1993 Jun;60(6):2167-74 [PMID: 8492124]
  19. Ann Intern Med. 2009 Apr 7;150(7):447-54 [PMID: 19349630]
  20. Psychopharmacology (Berl). 1977 Nov 24;55(1):19-26 [PMID: 414257]
  21. Psychopharmacology (Berl). 1989;97(1):131-8 [PMID: 2496419]
  22. Exp Clin Psychopharmacol. 2007 Oct;15(5):501-9 [PMID: 17924784]
  23. Psychopharmacology (Berl). 2007 Feb;190(2):157-70 [PMID: 17115136]
  24. N Engl J Med. 2010 Jun 17;362(24):2295-303 [PMID: 20554984]
  25. J Pharmacol Exp Ther. 2011 Oct;339(1):194-202 [PMID: 21730011]
  26. Biochem Pharmacol. 1997 Oct 1;54(7):743-53 [PMID: 9353128]
  27. Drug Metab Dispos. 1997 Jan;25(1):47-54 [PMID: 9010629]
  28. Pharmacol Biochem Behav. 2009 Jan;91(3):461-7 [PMID: 18817808]
  29. Synapse. 2007 Mar;61(3):157-65 [PMID: 17146768]
  30. JAMA. 2006 Jul 5;296(1):47-55 [PMID: 16820546]
  31. Prim Care Companion J Clin Psychiatry. 2010;12(2):null [PMID: 20694128]
  32. Behav Brain Res. 2011 Aug 1;221(1):314-9 [PMID: 21419807]
  33. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1455-64 [PMID: 20708056]
  34. Am J Psychiatry. 2014 Nov 1;171(11):1199-205 [PMID: 24934962]
  35. Mol Pharmacol. 2006 Sep;70(3):801-5 [PMID: 16766716]
  36. Nicotine Tob Res. 2009 May;11(5):572-6 [PMID: 19351781]
  37. J Pharmacol Exp Ther. 1998 Mar;284(3):1058-65 [PMID: 9495867]
  38. Behav Processes. 2009 May;81(1):136-9 [PMID: 19429207]
  39. Nicotine Tob Res. 2009 Mar;11(3):234-9 [PMID: 19246427]
  40. Behav Brain Res. 2007 Feb 12;177(1):134-41 [PMID: 17129619]
  41. Behav Neurosci. 2009 Feb;123(1):97-108 [PMID: 19170434]
  42. Psychopharmacology (Berl). 1980;68(3):283-6 [PMID: 6771812]
  43. Behav Neurosci. 2013 Jun;127(3):465-73 [PMID: 23731077]
  44. J Pharmacol Methods. 1982 Jun;7(4):289-99 [PMID: 7121010]
  45. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97 [PMID: 16171993]
  46. Psychopharmacology (Berl). 2009 Sep;205(4):655-65 [PMID: 19495728]
  47. Biochem Pharmacol. 2001 Dec 15;62(12):1597-603 [PMID: 11755112]
  48. Pharmacol Biochem Behav. 1980 Nov;13(5):647-51 [PMID: 7443734]
  49. Arch Int Pharmacodyn Ther. 1963;143:299-330 [PMID: 13996119]
  50. Neuropharmacology. 2014 Nov;86:181-91 [PMID: 25080073]
  51. Behav Processes. 2012 May;90(1):28-33 [PMID: 22119845]
  52. Pharmacol Biochem Behav. 2013 Dec;114-115:82-9 [PMID: 24201046]
  53. Psychopharmacology (Berl). 1989;97(3):295-302 [PMID: 2497478]
  54. Neuropharmacology. 2010 Jun;58(8):1237-45 [PMID: 20302882]
  55. Pharmacol Biochem Behav. 2009 Dec;94(2):319-28 [PMID: 19778551]
  56. Behav Pharmacol. 2013 Feb;24(1):45-54 [PMID: 23263484]
  57. Bioorg Med Chem Lett. 2001 May 7;11(9):1245-8 [PMID: 11354387]
  58. J Pharmacol Exp Ther. 1999 Mar;288(3):1053-73 [PMID: 10027843]

Grants

  1. R01 DA034389/NIDA NIH HHS
  2. DA034389/NIDA NIH HHS

MeSH Term

Animals
Conditioning, Psychological
Discrimination Learning
Dose-Response Relationship, Drug
Drug Substitution
Extinction, Psychological
Male
Nicotine
Nicotinic Agonists
Rats
Rats, Sprague-Dawley
Smoking Cessation
Varenicline

Chemicals

Nicotinic Agonists
Nicotine
nornicotine
Varenicline

Word Cloud

Created with Highcharts 10.0.0extinctionnicotinestimulusvareniclinebacknornicotineswitchingsharegeneralizationswitchGeneralizationcessationtherapyrespondingRatsadministrationsucroseexperimentsessionslowerdosesoverlapRATIONALE:PharmacotherapiesoftenutilizedaidsmokingmedicationtreatingdependencebecomecommonplaceAlthoughcommonlittleknownimpactinitialeffectssubsequentOBJECTIVES:beginfillgapunderstandingprojectdeterminedcompoundselementsalteredMETHODS:traineddiscriminatedgoal-trackingtaskfollowedintermittentaccesswithheldfollowingsaline1supplanted1-34-6examined2reverseinvestigatedstartassessedgeneratingcumulativedose-effectcurveRESULTS:traininggreaterreceivedpointcomparedreceivingWhereasaloneshowedCONCLUSIONS:pharmacotherapyimpedeenhancenicotine-trainingappears04mg/kgmayeffectpharmacologicalinterventionnicotine-evokedconditionedratsCumulative-doseExtinctionInteroceptionLearningNicotineNornicotineSmokingVarenicline

Similar Articles

Cited By (4)